Literature DB >> 15608432

The -174G/C polymorphism of the interleukin 6 gene is a hallmark of lacunar stroke and not other ischemic stroke phenotypes.

A Chamorro1, M Revilla, V Obach, M Vargas, A M Planas.   

Abstract

BACKGROUND AND
PURPOSE: The CC genotype of the -174 G/C interleukin (IL)-6 polymorphism has been associated with lacunar stroke. However, it remains unsettled whether this polymorphism is also associated with other ischemic stroke phenotypes.
METHODS: The -174 G/C IL-6 polymorphism was genotyped in patients with lacunar stroke (n = 89), stroke due to large vessel disease (n = 82), cardioembolism (n = 53), stroke of undetermined cause (n = 49) and in white controls without any history of stroke (n = 105) by PCR and restriction enzyme analysis. Independent predictors of the -174 G/C IL-6 genotypes were assessed using multivariate logistic regression models adjusted for demographics, risk factors and disease state.
RESULTS: The prevalence of the CC genotype was 8.5% in large vessel disease, 7.5% in embolism, 19.1% in lacunar stroke, 14.3% in stroke of undetermined cause and 8.6% in controls. The CC genotype was independently associated with lacunar stroke only (adjusted OR 3.22, 95% CI 9.09-1.12). Contrarily, there were no significant differences in genotype and allele distribution in the remainder of ischemic stroke phenotypes. Pooling of patients with nonlacunar stroke did not show any independent association with the CC genotype as compared with controls (OR 1.01, 95% CI 2.77-0.36).
CONCLUSIONS: The unique association between the CC genotype of the -174 G/C IL-6 polymorphism and lacunar stroke suggests a particular susceptibility of small deep penetrators of cerebral arteries to IL-6-mediated inflammatory damage. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15608432     DOI: 10.1159/000082785

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  16 in total

Review 1.  Genetics of stroke.

Authors:  Jin-min Guo; Ai-jun Liu; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 2.  The harms and benefits of inflammatory and immune responses in vascular disease.

Authors:  Angel Chamorro; John Hallenbeck
Journal:  Stroke       Date:  2006-01-12       Impact factor: 7.914

3.  Tumour necrosis factor alpha, ınterleukin 10 and ınterleukin 6 gene polymorphisms of ıschemic stroke patients ın south Marmara region of Turkey.

Authors:  Adile Ozkan; Fatma Sılan; Ahmet Uludağ; Yıldız Degirmenci; Handan Isin Ozisik Karaman
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

4.  Correlation between interleukin-6 promoter and C-reactive protein (CRP) polymorphisms and CRP levels with the Mainz Severity Score Index for Fabry disease.

Authors:  G Altarescu; G Chicco; C Whybra; S Delgado-Sanchez; N Sharon; M Beck; D Elstein
Journal:  J Inherit Metab Dis       Date:  2008-01-05       Impact factor: 4.982

Review 5.  Cerebral small vessel disease: genetic risk assessment for prevention and treatment.

Authors:  Ada Lam; M Anne Hamilton-Bruce; Jim Jannes; Simon A Koblar
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 6.  Genetics of atherothrombotic and lacunar stroke.

Authors:  Stéphanie Debette; Sudha Seshadri
Journal:  Circ Cardiovasc Genet       Date:  2009-04

7.  Small vessel cerebrovascular disease: the past, present, and future.

Authors:  Réza Behrouz; Ali R Malek; Michel T Torbey
Journal:  Stroke Res Treat       Date:  2012-01-24

8.  Association between Interleukin-6 (G174C and G572C) promoter gene polymorphisms and risk of ischaemic stroke: A meta-analysis.

Authors:  Pradeep Kumar; Arun K Yadav; Amit Kumar; Ram Sagar; Awadh K Pandit; Kameshwar Prasad
Journal:  Ann Neurosci       Date:  2015-04

9.  IL-6 Variants in Ischemic Stroke.

Authors:  Philipp G Sand
Journal:  Ann Neurosci       Date:  2016-03-11

10.  A study on the effect of IL-6 gene polymorphism on the prognosis of non-small-cell lung cancer.

Authors:  Wei Jia; Guang-He Fei; Jie-Gui Hu; Xian-Wei Hu
Journal:  Onco Targets Ther       Date:  2015-09-23       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.